LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

Lucid Diagnostics Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$0.38−0.10 (-21.05%)

Close on Oct 19, 2026

Market cap: $69.11M
P/E (TTM): –
Dividend yield: –

Lucid Diagnostics Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	4.71	4.35	2.43	0.38	0.50	–
Cost of Revenue	6.67	7.10	–	100	0.59	–
Gross Profit	-1.96	-2.75	–	0.38	0.50	–
Research & Development	5.68	5.99	7.25	11	9.30	5.44
Selling, General & Admin	42	37	36	40	0.02	0.01
Selling & Marketing	18	16	16	16	5.26	1.31
General & Administrative	24	20	19	24	13	1.53
Operating Expenses	–	50	51	57	28	8.28
Total Costs & Expenses	54	50	–	–	–	–
Operating Income	-50	-46	-48	-56	-27	-8.28
Interest Expense	0.02	0.03	0.42	0.01	0.66	–
Interest & Investment Income	0.39	0.32	0.42	0.09	–	–
Other Non-Operating Income	-8.37	0.52	-4.18	0.08	-0.66	–
Pretax Income	-58	-46	-53	-56	-28	-8.28
Income Tax Expense	0	0	–	–	–	–
Net Income	-58	-46	-53	-56	-28	-8.28
Net Income to Common	-71	-53	-53	–	–	–
EPS (Basic)(per share)	-0.69	-1.05	-1.26	-1.55	-1.51	-0.59
EPS (Diluted)(per share)	–	-1.05	-1.26	-1.55	-1.51	-0.59
Shares Outstanding (Basic, Weighted)(shares)	102	51	42	36	19	14
Shares Outstanding (Diluted, Weighted)(shares)	102	51	42	36	19	14
EBITDA	-49	-45	-46	-54	-27	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: -36.1%
Operating margin: -930.9%
Net margin: -959.8%
Return on equity, FY2025: -710.6%

Financial strength

Current ratio: 1.33
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 121.4%

Valuation

P/E ratio: –
Price to sales: 12.69
Price to book: 6.32
Dividend yield: –